Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;35(6):e15439.
doi: 10.1111/dth.15439. Epub 2022 Mar 18.

Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild-to-moderate hidradenitis suppurativa: A retrospective study

Elisa Molinelli  1 , Valerio Brisigotti  1 , Oriana Simonetti  1 , Claudia Sapigni  1 , Giovanni Marco D'Agostino  1 , Giulio Rizzetto  1 , Alfredo Giacchetti  2 , Annamaria Offidani  1
Affiliations

Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild-to-moderate hidradenitis suppurativa: A retrospective study

Elisa Molinelli et al. Dermatol Ther. 2022 Jun.

Abstract

Topical and systemic antibiotic therapy remains the first-line treatment for mild-to-moderate hidradenitis suppurativa (HS). However, literature data on antibiotic resistance in HS are growing. A total of 134 patients with mild-to-moderate HS were retrospectively evaluated. Seventy-three patients (group A) received topical clindamycin 1% and 61 patients (group B) received topical resorcinol 15%. We evaluated the efficacy and tolerability of topical 15% resorcinol versus topical 1% clindamycin in mild-to-moderate HS, comparing the clinical response at 12 weeks of treatment. Patients treated with resorcinol 15% showed a significant improvement in Hidradenitis Suppurativa Clinical Response, International Hidradenitis Suppurativa Severity Score System, and Pain Visual Analogue Scale score from baseline compared to patients treated with clindamycin 1%. Topical resorcinol 15% could be a valid alternative to clindamycin in the management of acute and long-standing HS, limiting antibiotic use and antimicrobial resistance.

Keywords: HS treatment; antibiotic; antibiotic resistance; clindamycin; hidradenitis suppurativa; resorcinol.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflict of interest.

References

    1. Offidani A, Molinelli E, Sechi A, et al. Hidradenitis suppurativa in a prepubertal case series: a call for specific guidelines. J Eur Acad Dermatol Venereol. 2019;33:28‐31. - PubMed
    1. Lacarrubba F, Dini V, Napolitano M, et al. Ultrasonography in the pathway to an optimal standard of care of hidradenitis suppurativa: the Italian ultrasound working group experience. J Eur Acad Dermatol Venereol. 2019;33:10‐14. - PubMed
    1. Bettoli V, Join‐Lambert O, Nassif A. Antibiotic treatment of hidradenitis suppurativa. Dermatol Clin. 2016;34:81‐89. - PubMed
    1. Zouboulis CC, Bechara FG, Dickinson‐Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33:19‐31. - PMC - PubMed
    1. Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa foundations: part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81:91‐101. - PMC - PubMed

MeSH terms